| Recruiting | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965 | Guangzhou University of Traditional Chinese Medicine | N/A |
| Not Yet Recruiting | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data NCT07287904 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Not Yet Recruiting | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC NCT07182708 | Peking University Cancer Hospital & Institute | Phase 2 |
| Active Not Recruiting | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lu NCT06685718 | BeOne Medicines | Phase 1 |
| Recruiting | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lu NCT06363734 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib i NCT06053099 | Intergroupe Francophone de Cancerologie Thoracique | N/A |
| Recruiting | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813 | TYK Medicines, Inc | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR NCT05778149 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brai NCT05768490 | Sun Yat-sen University | Phase 3 |
| Recruiting | CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease NCT05257967 | British Columbia Cancer Agency | N/A |
| Active Not Recruiting | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations NCT05258279 | Juntendo University | Phase 2 |
| Recruiting | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728 | TYK Medicines, Inc | Phase 3 |
| Active Not Recruiting | Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC NCT05244213 | Guangdong Provincial People's Hospital | Phase 2 |
| Completed | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation NCT05146219 | TYK Medicines, Inc | Phase 2 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Unknown | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patie NCT05136014 | Central Hospital, Nancy, France | — |
| Unknown | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC NCT04989322 | Dr Joanne CHIU | Phase 2 |
| Unknown | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis NCT04944069 | Second Affiliated Hospital of Nanchang University | N/A |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Completed | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs NCT04764214 | Fudan University | Phase 2 |
| Enrolling By Invitation | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma NCT06730477 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Unknown | Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSC NCT04768491 | Peking Union Medical College | — |
| Unknown | A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NS NCT04636593 | First People's Hospital of Hangzhou | Phase 2 |
| Completed | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation NCT04233021 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Unknown | Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation NCT04470076 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Unknown | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metast NCT04148898 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Unknown | Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study NCT04122833 | Konkuk University Medical Center | — |
| Unknown | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Pati NCT03647956 | The University of Hong Kong | Phase 2 |
| Unknown | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer NCT04425681 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Terminated | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung NCT02846792 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations NCT02949843 | Wake Forest University Health Sciences | Phase 2 |
| Completed | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression NCT03544814 | Shanghai Chest Hospital | Phase 2 |
| Terminated | Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC NCT02299765 | Sichuan University | Phase 4 |